AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)
Completed
- Conditions
- Major Depressive DisorderMDD
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT01344733
- Locations
- 🇮🇹
Research Site, Novara, Italy
PHARMO Institute Seroquel Safety Study
Completed
- Conditions
- SchizophreniaMajor Depressive DisorderBipolar DisorderGeneralized Anxiety Disorder
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2011-09-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18325
- Registration Number
- NCT01342120
Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2011-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT01340183
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT01340040
- Locations
- 🇯🇵
Research Site, Matsuyama, Ehime, Japan
Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 96
- Registration Number
- NCT01338350
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists
Completed
- Conditions
- Hospitalized Cases of Angioneurotic OedemaGastroenteritisSeizuresPneumoniaFailure to ThriveAcute Interstitial Nephritis and Thrombocytopenia
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23470
- Registration Number
- NCT01338363
- Locations
- 🇳🇱
Reserach Site, Utrecht, Netherlands
Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.
Phase 1
Completed
- Conditions
- Healthy VolunteersRheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT01336218
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
Phase 3
Completed
- Conditions
- Opioid-Induced Constipation (OIC)
- Interventions
- Drug: Usual care
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 844
- Registration Number
- NCT01336205
- Locations
- 🇺🇸
Research Site, Middleton, Wisconsin, United States
Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2015-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT01335451
- Locations
- 🇯🇵
Research Centre, Fukuoka, Japan
To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT01332214
- Locations
- 🇬🇧
Research Site, London, United Kingdom